|
|
|
| Serum LncRNA CASC15 LncRNA MALAT1 Expression and Clinical Significance in Hemodialysis Patients with End-Stage Renal Disease |
| FEI Bingru, ZHOU Hu, WANG Suyu, et al |
| The Affiliated Huaian First People's Hospital of Nanjing Medical University, Jiangsu Huai'an 223000, China |
|
|
|
|
Abstract Objective: To investigate the expression and clinical significance of serum LncRNA CASC15 and LncRNA MALAT1 in hemodialysis patients with end-stage renal disease. Methods: Patients with end-stage renal disease who underwent regular dialysis treatment in our hospital from January 2019 to December 2020 were selected as the research group,and 62 patients with CKD stage Ⅲ-Ⅳ who started dialysis treatment for the first time in our hospital were randomly selected according to the ratio of 1:1 as the control group.Blood samples were tested for creatinine (SCr),uric acid (UA),eGFR,total cholesterol (TC),triglycerides (TG),urea (BUN),haemoglobin,C-reactive protein (CRP),calcium and phosphorus by real-time fluorescence quantitative polymerase chain reaction (RT-PCR) based on SYBR Green method to amplify the target sequences.Patients in the study group were followed up for the occurrence of clinical endpoint times within 1 year of starting dialysis. Results: The expressions of serum LncRNA CASC15 and LncRNA MALAT1 in the study group were significantly higher than those in the control group (P>0.05).); LncRNA MALAT1 high expression of SCr,UA,BUN was higher than LncRNA MALAT1 low expression group,eGFR and hemoglobin were lower than low expression group,the difference was statistically significant (P<0.05); uremic patients with different LncRNA CASC15 expression levels developed cardiovascular disease.There were statistically significant differences in events and all-cause mortality (P<0.05),and differences in the expression levels of different LncRNA CASC15 and LncRNA MALAT1 for giving up treatment (all-cause death) were statistically significant (P<0.05).There was no significant difference in the incidence of cerebrovascular accident,serious infection and gastrointestinal bleeding among the expression level groups (P>0.05). Conclusion: LncRNA CASC15 and LncRNA MALAT1 are significantly up-regulated in the serum of end-stage renal disease hemodialysis patients,which are closely related to the clinical parameters of patients and the time of dialysis clinical endpoints,and are expected to be therapeutic targets for in-depth research.
|
|
|
|
|
|
[1] Kanda H,Hirasaki Y,Iida T,et al.Perioperative management of patients with end-stage renal disease[J].Cardiothorac Vasc Anesth,2017,31(6):2251-2267.
[2] Anderson CAM,Nguyen HA.Nutrition education in the care of patients with chronic kidney disease and end-stage renal disease[J].Semin Dial,2018,31(2):115-121.
[3] Tsuzuki T,Iwata H,Murase Y,et al.Renal tumors in end-stage renal disease:a comprehensive review[J].Int Urol.2018,25(9):780-786.
[4] Krolewski AS,Skupien J,Rossing P,et al.Fast renal decline to end-stage renal disease:an unrecognized feature of nephropathy in diabetes[J].Kidney Int,2017,91(6):1300-1311.
[5] 王蓉,袁涛.长链非编码RNA在恶性黑色素瘤侵袭和转移中作用的研究进展[J].中国肿瘤生物治疗杂志,2021,28(3):311-316.
[6] 朱培雯,史学佳,秦士杰,等.竞争性结合的LncRNA和miRNA作为标志物提高宫颈鳞癌患者的诊断和预后[J].南京师大学报(自然科学版),2020,43(4):53-61.
[7] Liu P,Zhang B,Chen Z,et al.m6A-induced lncRNA MALAT1 aggravates renal fibrogenesis in obstructive nephropathy through the miR-145/FAK pathway[J].Aging (Albany NY),2020,12(6):5280-5299.
[8] Zhou LJ,Yang DW,Ou LN,et al.Circulating expression level of lncRNA malat1 in diabetic kidney disease patients and its clinical significance[J].Diabetes Res,2020,2020:4729019.
[9] Qin X,Zhu S,Chen Y,et al.Long non-coding RNA (LncRNA) CASC15 is upregulated in diabetes-induced chronic renal failure and regulates podocyte apoptosis[J].Med Sci Monit,2020,26:e919415.
[10] Shi S,Yang J,Fan W,et al.Effects of LncRNA MALAT1 on microangiopathy and diabetic kidney disease in diabetic rats by regulating ERK/MAPK signaling pathway[J].Minerva Med,2020,111(2):184-186. |
|
|
|
2022, Vol. 28 
